Saud Bin Saeed, Hifza Idrees, Hammad Haider.
Comparison of HBA1C with Sitagliptin Plus Metformin and Pioglitazone Plus Metformin.
Pak J Med Health Sci Jan ;12(3):1248-50.

Background: Hyperglycemia had proven to be a major risk factor in microvascular complication developments in patients with Type II DM. Contrary to this many clinical trails proved the reduction in HbA1c can control the complication development in type II DM patients. Aim: To compare the HbA1c with sitagliptin + metformin and pioglitazone + metformin in patients with Type II Methods: This was an analytical study where the opted design was analytical prospective. All the patients were given the treatments randomly and assigned a group. Group I contained all patients, which were treated with sitagliptin + metformin as of their usual doses for 12 weeks, on the other hand group II was given pioglitazone + metformin for 12 weeks, the dose of treatment was usual as well. Results: A total of 120 patients were recruited for this study. Both The group contains 60 type II DM patients each. Group I was treated with sitagliptin + metformin and group II was treated with pioglitazone + metformin. In group I the mean age was 51.3 +/- 6.8 and in-group II was 54.45 +/-5.2 years. WE observed in our study that HbA1c level has been upgraded in group I from 8.7 +/-0.50 to 7.72 +/- 0.80 where the p value was 0.001, whereas in group II similar improvement were seen with significance value of 0.001. Conclusion: We may concluded in our study both the treatment options were effective to reduce the HbA1c, fasting blood glucose and blood glucose two hours after a meal and no significant difference was observed between the two treatment groups in improving the outcomes.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com